So, potential approach to enhance anti-leukemia is to improve T and NK dysfunction, such as PD-1 inhibitor, chimeric antigen receptor T-cell therapy, and NK or γδ T-based adoptive immunotherapies (63–65). This evidence concerns the gene PDCD1 and leukemia.